QP Release

Oral dosage forms (tablets, capsules, oral liquids)Actives and placebos

Primary and Secondary packaging and labelling capabilities 

https://eramol.com/clinical-services-category/clinical-packaging/

https://eramol.com/clinical-services-category/labelling-solutions/

Eramol specialises in early-phase sterile fill-finish, including aseptic processing, terminal sterilisation, sterile vial manufacturing, clinical packaging, UK & EU QP release and clinical trial supply.

Aseptic and Terminal sterilisation small molecule large molecule/biologics ADCs ATMPS...

Storage and global distribution capabilities 

https://eramol.com/clinical-services-category/clinical-storage-distribution/

Early-phase sterile fill-finish programmes often rely on limited quantities of valuable drug substance. Low line losses help maximise finished units, reduce API waste and improve clinical supply confidence. By combining efficient process design, Grade A isolator technology and experienced technical oversight, Eramol helps sponsors protect valuable material while supporting high-quality aseptic processing, terminal sterilisation and early-phase sterile manufacturing.

Eramol’s new sterile manufacturing facility at its Sevenoaks campus is a purpose-built, EU GMP Annex 1 aligned site designed to support early-phase sterile injectable programmes. The facility features isolator-based aseptic fill-finish and terminal sterilisation, with phase-appropriate batch sizes and a strong focus on sterility assurance and product protection, achieving <1% line losses. Fully integrated with Eramol’s wider services, the facility provides an end-to-end sterile solution including packaging and labelling, QC testing, UK/EU QP release, regulatory support, GMP/GDP storage and global distribution, with planned expansion to support later-stage and commercial manufacturing.